2020 Shortlist review

Back | Best Communication Award | Breakthrough of the Year AwardBest Technology Award
Mediscience Commentator of the Year Award | Capital Market Transaction of the Year Award
Most Significant Contribution to the Mediscience Sector Award The Emerging Star Award
Chief Executive of the Year Award | Company of the Year Award 

Best Communication Award 

Sponsored by Optimum Strategic Communications  


Successful communication is vital to the development of mediscience companies.

Newsflow, both good and bad, can have a significant effect on share prices, and the winner of this award will have demonstrated its ability to successfully communicate its investment message to its target audience. 

As always in this category, a benchmarking exercise was conducted on all nominated companies by Corporate Reporting specialists, Design Portfolio. The findings of this exercise were subsequently presented to the Voting Panel by Daniel Redman, Design Portfolio’s Content and Strategy Director. 

The 2020 finalists: 



Cambridge-based Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to research and clinical communities.

Abcam have a very active IR team who ensure their communication is both clear and consistent. The group’s Annual Report was one of the highest scorers in the benchmarking exercise and clearly communicates the strategic progress made by the company. The website contains some excellent navigational tools in addition to a wealth of content for shareholders and investors.

Abcam held its first Capital Markets Day in November 2019 which the Voting Panel noted as being extremely well attended and very well received.





argenx SE 


Belgium-based argenx is a global immunology company. 

The company is known for its consistently outstanding investor communication. It was noted by the Voting Panel that Argenx communicates with clarity and transparency and the group regularly publishes its strategic goals and timelines across all aspects of the business. argenx has been very active during the period under review and has maintained regular communication with stakeholders throughout.

argenx has a solid investor website which scored well in the benchmarking exercise. The group’s IR team held a large number of conferences and business updates across the year.   


Calliditas Therapeutics 


Stockholm-based Calliditas Therapeutics is a clinical-stage biopharmaceutical company with an initial focus on renal and hepatic diseases. 

2019 was an exceptional year for Calliditas, with the group achieving many major milestones, culminating in its NASDAQ IPO. For the period under review, the Voting Panel acknowledged that Calliditas maintained very clear messaging with its stakeholders, in addition to ensuring significant financial disclosure above and beyond the expected level. 

The group’s Annual Report broke fresh ground with an interview with the founder of a renal disease foundation. Calliditas held an informative Capital Markets Day at the end of last year.

Ergomed plc


Surrey-based Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. 

Ergomed is another company that had a transformational year last year. This was reflected in its investor communications. The Voting Panel noted that Ergomed’s new CEO had a large volume of news to communicate, involving some complex transactions, and this was done effectively and with complete transparency. The group’s recent involvement in providing services to the re-purposing of three compounds for critically ill patients with COVID-19 has also been communicated to the investor audience with clarity.